1B1.SI Stock Surges 6.76% on High Volume Trading in Singapore

HC Surgical Specialists Limited (1B1.SI) delivered a solid intraday performance on the Singapore Exchange (SES), climbing 6.76% to close at S$0.395 on April 28, 2026. The healthcare provider saw trading volume spike to 163,700 shares, significantly above its 14,104-share daily average. This surge reflects renewed investor interest in the medical diagnostics and surgical services sector. 1B1.SI stock has shown resilience over the past year, gaining 40.74% from its 52-week low of S$0.27. The company operates a network of clinics offering endoscopic procedures, colorectal surgery, orthopedic services, and diagnostic testing across Singapore.

1B1.SI Stock Performance and Market Sentiment

HC Surgical Specialists delivered a strong intraday move, with 1B1.SI stock climbing 6.76% on elevated trading activity. The stock opened at S$0.395 and maintained that level through the session, with volume reaching 163,700 shares—nearly 12 times the average daily turnover.

Trading Activity

The surge in volume signals growing institutional and retail participation. 1B1.SI stock trades at a market capitalization of S$58.3 million with 153.4 million shares outstanding. Year-to-date, the stock has gained 4.11%, outperforming many healthcare peers. The 50-day moving average sits at S$0.3645, while the 200-day average rests at S$0.3519, indicating an uptrend structure.

Liquidation and Support Levels

Technical indicators show the stock trading near resistance. The Bollinger Bands upper band sits at S$0.39, with the middle band at S$0.37 and lower band at S$0.36. The Relative Strength Index (RSI) stands at 60.37, suggesting moderate momentum without overbought conditions. Money Flow Index (MFI) at 69.07 indicates strong buying pressure. Support remains solid at the 200-day moving average of S$0.3519.

Valuation and Financial Metrics of 1B1.SI Analysis

1B1.SI analysis reveals attractive valuation metrics compared to healthcare sector peers. The stock trades at a PE ratio of 6.33, well below the sector average of 22.28. This discount reflects market skepticism despite strong operational fundamentals.

Key Valuation Ratios

The price-to-book ratio stands at 2.79, while the price-to-sales ratio is 4.07. Earnings per share (EPS) reached S$0.06 over the trailing twelve months. The dividend yield is 5.47%, making 1B1.SI stock attractive for income-focused investors. Free cash flow yield of 8.80% demonstrates solid cash generation relative to market value.

Profitability and Efficiency

HC Surgical Specialists maintains impressive margins. Net profit margin reaches 47.09%, while operating margin stands at 45.28%. Return on equity (ROE) of 34.20% and return on assets (ROA) of 24.75% significantly exceed healthcare sector averages. The company generates S$0.0334 in free cash flow per share, supporting dividend sustainability.

HC Surgical Specialists Limited Stock Grade and Outlook

Meyka AI rates 1B1.SI with a grade of B, reflecting a balanced risk-reward profile. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The overall score of 67.06 suggests a HOLD recommendation for current investors.

Strengths and Concerns

Strengths include exceptional ROE and ROA metrics, strong dividend yield, and low debt levels. The debt-to-equity ratio of just 0.13 provides financial flexibility. However, the DCF score of 1 with a Strong Sell recommendation raises valuation concerns. The company’s PEG ratio of 0.074 indicates potential undervaluation on a growth-adjusted basis.

Price Forecast and Targets

Meyka AI’s forecast model projects a monthly price target of S$0.35, implying modest downside from current levels. The quarterly forecast stands at S$0.12, suggesting volatility ahead. These forecasts are model-based projections and not guarantees. Track 1B1.SI on Meyka for real-time updates and technical analysis.

Healthcare Sector Context and Growth Drivers

HC Surgical Specialists operates within Singapore’s healthcare sector, which has shown mixed performance recently. The broader healthcare sector trades at an average PE of 22.28 with net margins of 23.84%. 1B1.SI stock’s lower valuation reflects its smaller scale compared to peers like IHH Healthcare (Q0F.SI).

Service Expansion Opportunities

The company’s diversified service portfolio—spanning endoscopy, orthopedics, home care, and diagnostics—positions it well for demographic shifts. Singapore’s aging population drives demand for surgical and diagnostic services. The company’s 180 full-time employees operate clinics across Singapore, with headquarters at 233 River Valley Road.

Competitive Positioning

With a market cap of S$58.3 million, HC Surgical Specialists remains a niche player. However, its focus on colorectal and endoscopic procedures addresses a growing market segment. The company’s ability to maintain 47% net margins while competing against larger healthcare providers demonstrates operational excellence and pricing power in its specialized niches.

Final Thoughts

HC Surgical Specialists Limited (1B1.SI) presents a mixed investment case on April 28, 2026. The 6.76% intraday surge reflects renewed interest in this healthcare specialist, though elevated volume may signal profit-taking ahead. The stock’s B grade from Meyka AI, combined with exceptional profitability metrics and a 5.47% dividend yield, appeals to value and income investors. However, the DCF-based valuation concerns and modest price forecasts warrant caution. The company’s strong ROE of 34.20%, low debt, and specialized market position provide downside protection. Investors should monitor quarterly earnings announcements scheduled for July 28, 2025, and track sector trends. …

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.